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A B S T R A C T
Equine influenza virus (EIV) is a major respiratory pathogen of horses despite the availability of equine
influenza vaccines. This study aimed to determine genetic evolution of EIV strains in France between 1967 to
present. A whole genome comparative analysis was also conducted on recent French strains in order to identify
potential factors of pathogenicity. Comparison of French EIV sequences with vaccine and worldwide epidemic
strains revealed amino acid substitutions in both haemagglutinin (HA) and neuraminidase, especially within the
antigenic sites and/or close to receptor binding sites (HA). Amino acid substitutions were also identified in
other genes, mainly the polymerase complex proteins and PB1-F2. Viruses belonging to Eurasian and American
lineages have circulated until 2003 and Florida sub-lineage Clade 2 strains predominates since 2005. The last
French strain (2015) displayed several specificities in HA suggesting the occurrence of antigenic drift with
presence of pathogenic markers in the PA and PB1-F2 genes.
1. Introduction
Equine influenza virus (EIV) is an influenza A virus belonging to the
Orthomyxoviridae family and is considered to be one of the respiratory
pathogens causing the greatest economic losses to the equine industry.
Equine influenza virus is highly contagious, endemic in most parts of
the world and has the potential to disrupt major equestrian events
(Landolt et al., 2013). H3N8 EIV was first isolated during an outbreak
in Miami (USA) in 1963 and since the late 1980's, has been the only
subtype causing major equine outbreaks worldwide (Webster, 1993;
Gildea et al., 2011; Legrand et al., 2013; Woodward et al., 2014). The
H3N8 subtype has continually evolved, diverging at the end of the
1980's into two antigenically distinct lineages, American and Eurasian.
The American lineage has diverged further into Argentinian, Kentucky
and Florida sub-lineages (Daly et al., 1996; Lai et al., 2001). Evolution
of the Florida sub-lineage has resulted in the emergence of two clades,
1 and 2, which are currently circulating worldwide (Bryant et al., 2009;
Gildea et al., 2011; Laabassi et al., 2015; Virmani et al., 2010;
Yamanaka et al., 2008). The EIV strains isolated in France typically
follow the same evolutionary pattern, but available information is
limited (Legrand et al., 2013; Manuguerra et al., 2000).
It is well established that mammalian influenza viruses undergo
antigenic drift through amino acid substitutions within the viral
glycoproteins haemagglutinin (HA) and neuraminidase (NA).
Modifications in the domains carrying one or several antigenic sites
can diminish influenza vaccine efficacy and lead to recurrent outbreaks.
The HA1 domain appears to be under the most selective pressure
induced by the neutralising antibodies (Nelson and Holmes, 2007). The
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OIE Expert Surveillance Panel (ESP) annually reviews EIV evolution,
especially antigenic drift, in order to recommend updates of the EI
vaccine strain composition (OIE World Organisation for Animal
Health, 2015) to prevent and mitigate the risks of vaccine breakdown
(Woodward et al., 2015). This illustrates the importance of surveillance
programs focusing on HA and NA genes encoding two EIV surface
glycoproteins. However, other genes are also associated with influenza
virus virulence and monitoring of potential novel markers for patho-
genicity, such as PB1-F2, may additionally be required Alymova et al.
(2014a), (2014b).
This study aimed to compare HA and NA sequences from EIV
strains isolated during major French EI outbreaks since 1967 in order
to determine their genetic evolution during the last 5 decades. Whole
genomes from a panel of recent French EIV strains were also
sequenced and potential factors of pathogenicity were highlighted.
2. Materials and methods
2.1. Sample collection
Equine influenza viruses were isolated from sick horses during
respiratory disease outbreaks that occurred in France from 1967 to
2003 by the French Agency for Food, Environmental and Occupational
Health & Safety (ANSES) and since 2005 by the RESPE-associated
veterinarians (Legrand et al., 2013) and LABÉO Frank Duncombe.
After collection, nasopharyngeal swabs were placed immediately in
5 ml of virus transport medium containing minimum essential medium
supplemented with 10% of fetal bovine serum and 1% antibiotics
(Penicillin, Streptomycin and Amphotericin).
2.2. Extraction of nucleic acids and EIV diagnosis
RNA was extracted from 140 µl of respiratory fluids using the
QIAamp Viral RNA Mini Kit (Qiagen, Courtaboeuf, France) according
to the manufacturer's recommendations. For detection of EIV, two one-
step RT-PCR were performed using equine-specific M1 primers: period
2005–2009 (Legrand et al., 2013); period 2010–2016 adapted from
(Heine et al., 2007).
2.3. Genes sequencing and analysis
The HA and NA sequences from French EIV outbreak isolates were
determined (30 and 28, respectively). The phylogenetic analysis was
carried out for HA1 only due to a limited number of complete HA
sequences available in GenBank for reference and comparison. The
strains A/equine/Jouars/4/2006, A/equine/Belfond/6-2/2009, A/
equine/Neuville-Pres-Sees/1/2011, A/equine/Cambremer/1/2012, A/
equine/Gironde/1/2014 and A/equine/Saone-et-Loire/1/2015 were
fully sequenced.
For EIV strains isolated between 1967 and 2003, viral genome
extracted were reverse transcribed into cDNA using SuperScript III
(Thermo scientific), cDNA syntheses were performed using the influ-
enza universal primer AGCAAAAGCAGG. PCR amplification from
2.5 µl of cDNA products was performed using the PCR extender system
(5Prime) following the manufacturer's instructions. During the first
cycle, samples were incubated at 94 °C for 2 min followed by 35 cycles
with the following conditions: 94 °C for 20 s, 55 °C for 20 s, 72 °C for
2 min. The program ended with one cycle at 72 °C for 10 min. Primers
used for amplification were Eq/H3/9F (CAGGGGATATTT
CTGTCAATCATG) or H3HA11F (AGCAAAAGCAGGGGATATTTCTG)
(Ilobi et al., 1998) and Eq-H3-1741R (AGTAGAAACAAGGGT
GTTTTTAAC) or EH3-1686R (GCATCTGATGTTGCCTTTTTGGC) for
HA gene and Eq/N8/2F (GCAAAAGCAGGAGTTTAAAATG) and Eq/
N8/1460R (GTAGAAACAAGGAGTTTTTTTCG) for NA gene
(Manuguerra et al., 2000).
For EIV strains isolated since 2005, genes were amplified in two-
steps after extraction. The first step was the reverse transcriptase using
Superscript II (Thermo Scientific) followed by an amplification (second
step). PCR products were generated using Phusion Hot Start II high-
fidelity DNA polymerase (Thermo Scientific). HA and NA were
amplified according to Cullinane process (Cullinane, personal commu-
nication) and other genes (PB2, PB1, PA, NP, M and NS) with M13
primer sequences as described previously (Rash et al., 2014).
Sequencing was performed by Biofidal (Vaulx en Velin, France) using
the Sanger method. Sequences were assembled and contigs were
analysed with the CodonCode Aligner v1.5.2 software (CodonCode
Corporation, Dedham, USA). A multiple alignment of all sequences was
conducted using the Muscle algorithm and neighbor-joining trees
method (MEGA V6 software (Tamura et al., 2013)), with a maximum
likelihood substitution model and bootstrapped 1000 times to assess
the reliability. Additional strains were added to compare conserved
mutations between the French EIV strains and vaccine or outbreak
strains, such as A/equine/Hong Kong/1/1992, A/equine/Sydney/
6085/2007 and A/equine/Dubai/1/2012. The amino acid sequences
of other viral proteins (PB2, PB1, PB1-F2, PA, PA-X, NP, M1, M2, NS1,
NS2-NEP) from recent EIV isolated in France were aligned with the
amino acid OIE-ESP recommended strain A/equine/Richmond/1/
2007. The strain A/equine/Jouars/4/2006 was not analysed for PB1-
F2 due to lack of the beginning of the nucleic acid sequence of the
segment PB1. The workflow is summarised in the Supplementary
Fig. 1.
3. Results
3.1. Phylogenetic analysis
Analysis of the HA1 nucleotide sequences generated from the
French EIV strains and other EIVs retrieved from GenBank showed
six distinct clusters. The 30 French EIV strains analysed were located
within 5 out of the 6 clusters Fig. 1. The HA1 sequences of the 15
viruses isolated between 1973 and 1997 were found within the Pre-
divergent lineage. While the 3 viruses isolated between 1999 and 2003
belonged to Eurasian lineage. An EIV strain belonging to the Florida
Clade 1 was isolated during the Grosbois epidemic in 2009. The strain
A/equine/Grosbois/1/1999 was located within the Kentucky lineage.
From 2005, nine EIV isolates analysed in this study belonged to Clade
2 of the Florida sub-lineage. Overall, these observations for the HA1
gene were correlated with the complete NA sequence analysis, illu-
strated in Fig. 2. However, we observed a lack of homogeneity for the
strain A/equine/Cambremer/1/2012 between HA1 and NA sequence
analyses (99% for HA1 and 98% NA compared to A/equine/Saone-et-
Loire/1/2015).
3.2. Comparison of HA amino acid alignment
The HA amino acid sequences of the 30 French EIV strains isolated
since the early 70 s were compared to A/equine/Miami/1/1963. The
amino acid substitutions are represented in Table 1 and Supplementary
Fig. 2.
In most cases, when a specific amino acid substitution has occurred
in several strains of the Pre-divergent lineage, it was conserved into
other clusters (i.e. G6S, T46I, V102I, L111I, M121T, S137G, R140K,
E158G, T187S, V196I, A198E, V242I, I267V, V309I, S312N, Q324P,
K387R, N464G, D489Y and R503K). However, the amino acid
substitutions R140K, T187S, V196I and I267V, which appeared in
1985, have not been found in the later EIV strains A/equine/France/1/
1991, A/equine/Grosbois/1/1993 and A/equine/Grosbois/1/1997.
The amino acid substitutions T48I and D172N specific to the Pre-
divergent lineage, which were located in antigenic sites C and D,
respectively, further mutated (I48M andN172K) from 1999 and 1989,
respectively. Comparison of HA amino acid sequences showed that in
most cases, the substitutions that appeared in the Eurasian and/or
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American lineages (i.e. Kentucky and Florida sub-lineages) were
subsequently conserved in French strains from the same cluster
collected afterwards, such as amino acid substitutions N189Q, R261K
and T276I for the American lineage. The amino acid at position 189
also underwent an additional change (N189K) that was only found in
the Eurasian lineage. Moreover, this lineage is distinguished from the
American lineage by 8 additional amino acid substitutions T163I,
N189K, K207E, I213V, P273L, E280K, V300I and M462I. Within the
American lineage, representative strains of the Florida sub-lineage
Clade 1 and Clade 2 differed by 9 amino acids: 4 specific substitutions
of the Clade 1 viruses (R62K, V78A, D104N and V223I) and 5 specific
substitutions of the Clade 2 viruses (P103L, V112I, S159N, A372T and
G379E). The residue at position 7 showed two substitutions (G7D and
G7N), which appear to be representative of clades 1 and 2, respectively.
The amino acid substitution G7N was found in all strains belonging to
the Florida sub-lineage Clade 2 except for A/equine/Jouars/4/2006
and A/equine/Cagnes-sur-Mer/2/2011, which possess the amino acid
substitution G7D found mostly within the strains belonging to the
Florida sub-lineage Clade 1. Within this clade, the substitutions R62K
and V78A were both found in the antigenic site E. The amino acid
substitution S159N, specific to the Florida sub-lineage Clade 2, is
located in the antigenic site B. The reverted substitution N159S was
observed in all strains belonging to the Florida sub-lineage Clade 1.
The HA1 sequence from the French strain A/equine/Saone-et-
Loire/1/2015 differed by 8 residues when compared to other strains
belonging to the same clade. This strain possessed the amino acid
substitutions T131N, A144T, T179V, T192K, Q197R, I282V, R321K
and I527V. The substitutions T179V and T192K were also found in the
French strains A/equine/Bayeux/14/2005, A/equine/Cambremer/1/
2012 and in the Italian strain A/equine/Rome/1/2014, and the
substitution I527V was also present in the French strains A/equine/
Grosbois/13/2009 and A/equine/Belfond/6-2/2009 and the
Australian strain A/equine/Sydney/6085/2007. The residue 144 un-
derwent another substitution (A144V) in the strains A/equine/Ain/1/
2014 and A/equine/Gironde/1/2014. The HA amino acid alignment of
the strain A/equine/Saone-et-Loire/1/2015 showed the presence of 3
new substitutions within the antigenic sites A (A144T) and B (T192K
and Q197R) and 1 new substitution close to the antigenic site A
(T131N).
The study highlighted 204 synonymous/silent mutations. We
observed that some of these residues involved in a silent mutation
that subsequently underwent another mutation with a change of amino
acid, such as observed at position 58 (in all strains belonging to both
clades of the Florida sub-lineage), position 110 (in Florida sub-lineage
Clade 2 strains isolated since 2011), position 261 (in American lineage
strains), position 280 (only in Eurasian lineage strains) and position
379 (in Florida sub-lineage Clade 2 strains).
3.3. Comparison of NA amino acid alignment
The NA amino acid sequences of the French strains were compared
to A/equine/Miami/1/1963 (Supplementary Fig. 3). Twenty-one ami-
no acid substitutions that appeared within the Pre-divergent lineage
were subsequently preserved in other lineages: L17I, V18L, S37N,
E76R, S84N, L125S, E160K, V161I, A174S, H205N, V213I, Q250K,
N268S, V289I, V301I, S341N, Q342K, N355T, K390R, V394I and
V452I. However, residue 17 underwent another amino acid substitu-
tion (L17V) which was only observed in the French isolates belonging
to the Eurasian lineage. The reverted substitution I452V was observed
Fig. 1. Phylogenetic analysis of the HA1 nucleotide sequence for 95 EIV strains,
including representative strains of the main lineages, sub-lineages and vaccine strain
(*). The French strains highlighted with a colored dot: French strains belonging to the
Pre-Divergent lineage (black) except for the French strains isolated in the 1990s (red),
French strains belonging to the Eurasian lineage (purple), French strain belonging to the
Kentucky sublineage (blue), French strains belonging to the Florida sublineage clade 1
(orange) and French strains belonging to the Florida sublineage clade 2 (green).
Neighbor-Joining, Test phylogeny: Bootstrap method with 1000 bootstrap replication,
Mode/method: Maximum composite Likelihood. MEGA6: Molecular Evolutionary
Genetics Analysis Version 6.0 Tamura K, Stecher G, Peterson D, Filipski A, and Kumar
S (2013) Molecular Biology and Evolution 30:2725-2729.
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in the strain A/equine/Saone-et-Loire/1/2015. The residue 198 pre-
sented a first substitution (A198T) in 1979 followed by a second
mutation (T198N) in strains isolated since 1985 except for the French
strains isolated in 1991, 1993 and 1997. In regards to the residues at
position 125, 161, 174, 205, 268, 289, 342 and 355, the substitutions
observed were not present in the four French strains isolated in 1991,
1993, 1997 and 2000. The reverted substitution K342Q and S268N
were also found in the French strain A/equine/Grosbois/1/2003 and
A/equine/Sydney/6085/2007, respectively. The amino acid substitu-
tions T9A and I70T, appeared within the Pre-divergent lineage but
were no longer observed into the Florida sub-lineage Clade 2. This late
residue underwent a new substitution (I70A), which was only present
within the Florida sub-lineage Clade 2. These substitutions were one of
those distinguishing between the current Clade 1 and Clade 2. The
amino acid changes representative of current Clade 1 were: S337N
(since 2007), S12F, V35A, G40R, G42D, R260K (since 2009), and
G416E. This last substitution was also found for the Eurasian strain A/
equine/Grosbois/2/1999. The amino acid substitutions G40E, Y66H,
S78P, R109K (from 2011 with the exception of A/equine/Cambremer/
1/2012), V191I (also observed for 5 strains belonging to the Pre-
divergent lineage) and D235N (substitution also found in French
strains isolated in 1986 and 1987) seems to be representatives of the
Clade 2. Moreover, the strain A/equine/Gironde/1/2014 presents
three novel mutations at NA positions 25,42 and 48. The importance
of these mutations for NA is unknown.
This comparison of sequences highlighted 164 synonymous/silent
mutations subsequently displayed non-synonymous substitutions.
3.4. Comparison of other viral proteins
The amino acid sequences of other viral proteins (PB2, PB1, PB1-
F2, PA, PA-X, NP, M1, M2, NS1, NS2-NEP) from recent French EIV
strains Clade 2 (the oldest was A/equine/Jouars/4/2006) were com-
pared with the strain A/equine/Richmond/1/2007, an OIE-recom-
mended Florida Clade 2 strain for EI vaccine composition (Fig. 3). The
EIV strain A/equine/Saone-et-Loire/1/2015 exhibited more important
changes in its protein sequences relative to A/equine/Richmond/1/
2007. This strains from 2015 possess amino acid substitutions in the
polymerase basic 1 (PB1; 13 substitutions) and the polymerase acid
(PA; 11 substitutions). Some substitutions were highlighted for all 5
French EI strains FC2 but only few of them were preserved in the
strains isolated since 2011, such as PB2 S107N, PB1 T221A, PB1-F2
D50V, PA K158R, NP N473S, M1T168I and M2 D21G.
The analysis of the gene product PB1-F2, which is encoded by a +1
reading frame shift of PB1, showed a large number of substitutions.
PB1-F2 is the protein which presents the highest percentage of
substitutions (9.9%) when compared to other proteins (M2=8.3%;
M1=3.6%; NS1=3.2%; PA=2.5%; PB1=2.5%; NS2-NEP=1.7%; PA-
X=1.6%; NP=1.4% and PB2=1.2%). HA and NA remains however,
proteins that have the highest percentage of substitutions (HA=12.2%;
NA=11.9%).
The PB1-F2 analysis showed that the sequences of the EIV strains
A/equine/Cambremer/1/2012 and A/equine/Saone-et-Loire/1/2015
differ at a terminal position (amino acid residue 75). The amino acid
substitution R75H was present only in this two French strains. PB1-F2
from A/equine/Saone-et-Loire/1/2015 is 90 amino acids long when
compared with an 81 amino acid length for the other strains (Fig. 4).
Concerning the French strain belonging to Florida sub-lineage
Fig. 2. Phylogenetic analysis of the NA nucleotide sequence for 77 EIV strains, including
representative strains of the main lineages, sub-lineages and vaccine strain (*). The
French strains highlighted with a colored dot: French strains belonging to the Pre-
Divergent lineage (black) except for the French strains isolated in the 1990s (red), French
strains belonging to the Eurasian lineage (purple), French strain belonging to the
Kentucky sublineage (blue), French strains belonging to the Florida sublineage clade
1(orange) and French strains belonging to the Florida sublineage clade 2 (green).
Neighbor-Joining, Test phylogeny: Bootstrap method with 1000 bootstrap replication,
Mode/method: Maximum composite Likelihood. MEGA6: Molecular Evolutionary
Genetics Analysis Version 6.0 Tamura K, Stecher G, Peterson D, Filipski A, and Kumar
S (2013) Molecular Biology and Evolution 30:2725-2729.
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Clade 1A/equine/Belfond/6-2/2009, this strain possessed a low num-
ber of substitutions compared to A/equine/Ohio/1/2003, an OIE-
recommended Florida Clade 1 strain for EI vaccine composition
(Fig. 5). Only PB2, PB1, PA, PA-X, PB1-F2, M2 and NS1 proteins are
concerned. Like for the French Florida Clade 2 strains (with the
exception of A/equine/Saone-et-Loire/1/2015), PB1-F2 from A/
equine/Belfond/6-2/2009 possessed a sequence of 81 amino acids
(Fig. 4).
4. Discussion
Since the first isolation of EIV subtype H3N8 in Miami 1963,
several major outbreaks have occurred, most notably, Hong Kong 1992
(Watkins et al., 1993), Sydney 2007 (Watson et al., 2011) and Dubai
2012 (Woodward et al., 2014). Despite the development and commer-
cialisation of EI vaccines, EIV continues to circulate in many countries,
suggesting that vaccine coverage is sub-optimal and/or the viruses
undergo significant antigenic drift.
The EIV outbreak strains that were isolated in France for the past 5
decades illustrate the evolution of H3N8 viruses. Results are consistent
with previous studies (Damiani et al., 2008; Murcia et al., 2011) that
have determined lineages distinguished by both decade and location.
Thereby, the phylogenic analysis demonstrated that strains isolated
between 1967 and 1997 belong to Pre-divergent lineage whereas
strains responsible for the outbreaks between 1999 and 2003 belong
to the Eurasian lineage. However, the first appearance of EIV strains
belonging to the Eurasian lineage appeared to be delayed in France
when compared to the rest of Europe. It is surprising to observe that
the strains isolated from 1991 to 1997 in France were still present
within the Pre-divergent lineage, which is closer to strains isolated in
the early 80 s, while other strains isolated in Europe at this period
belonged to the Eurasian lineage (Borchers et al., 2005; Lewis et al.,
2011). Early amino acid substitutions within the French strains were
consistent with recently published observation (Woodward et al.,
2015). In our study, we found the same amino acid substitutions for
the HA at position 46, 55, 140, 159, 163, 172, 187, 189, 196, 207, 213,
260, 267 and 310. These amino acid changes appeared in most of the
cases during the mid 80's and were subsequently conserved within the
Eurasian and American lineages except for the amino acid substitu-
tions T163I, K207E and I213V, present only in the strains belonging to
the Eurasian lineage. The P55S, substitution which appeared in 1985,
is very interesting as it causes the occurrence of a new glycosylation site
and could play a major role by masking the antigenic site C to antibody
recognition (Munk et al., 1992; Skehel et al., 1984).
In 1999, EIV strains from both the Eurasian and Kentucky lineages
co-circulated in France. This was the first isolation of a strain belonging
to an American lineage in France. It is interesting to note that the
majority of substitutions which occurred within the Pre-divergent
Eurasian and Kentucky lineages were either conserved in time or
replaced by a new amino acid substitution as it was the case for HA
residues at position 48, 78, 172 and 189. This last amino acid is
involved in the receptor binding site for sialic acid (including the HA
190-helix) (Koel et al., 2013) and is often responsible for major
antigenic change in association with others substitutions (such as
Table 1
Amino acid alignments of five antigenic sites A to E between HA sequences determined for French strains (30 strains) and vaccine strains (*) or viral strains causing large-scale
outbreaks worldwide (°) compared with A/equine/Miami/1/1963. The antigenic sites defined for human H3 influenza virus was used as a reference (Both et al., 1983).
S. Fougerolle et al. Virology 505 (2017) 210–217
214
amino acid at position 158 and 159). This study also showed that the
loss of an amino acid substitution by restoring the original residue is a
rare phenomenon and was only observed for the residue 159 in all
strains belonging to the Florida sub-lineage Clade 1. The amino acid
substitution S159N appeared after 1973 and was not found in any
strains belonging to the Florida Clade 1. This residue is located within
the HA 150-loop described as being involved in the binding site of
neutralising monoclonal antibodies (Lee et al., 2012). The sequences
and conformations of the receptor binding site outer loops are essential
for binding and the main antibody target. A change in the sequence can
lead to immune escape. It appears that the amino acid Gly158 interacts
with heterosubtypic antibody and is stabilized by a hydrogen bond
formed between Ser159 and an amino acid of this antibody. A
substitution at position 158 or 159 could have an impact on antibodies
recognition (Lee et al., 2012).
Most of the EIV strains circulating in Europe in recent years belong
to Florida Clade 2 (Bryant et al., 2009; Gildea et al., 2011). This is
supported by our study, which indicates that strains isolated from
French outbreaks since 2005 were also located within the Florida Clade
2 cluster, with the exception of a large-scale outbreak in 2009 that
belongs to Florida Clade 1 (Legrand et al., 2013).
Since 2010, the OIE-ESP recommends the incorporation of repre-
sentative EIV strains from both Florida Clade 1 and Clade 2 into EI
vaccines (OIE World Organisation for Animal Health, 2010).
Comparison of HA sequences highlight several substitutions between
the French EIV strains and the OIE-recommended strain A/equine/
Richmond/1/2007 (Florida Clade 2), such as amino acid substitutions
P103L, A144V, I282V, V300I and I527V. The strain A/equine/Saone-
et-Loire/1/2015 can be of great interest as this strain presents ten
substitutions when compared to A/equine/Richmond/1/07, with three
of which (A144T, T192K and Q197K) are located in antigenic sites (site
A for the first residue and site B for the other two) with one close to the
antigenic site A (T131N). Accumulation of these amino acid substitu-
tions within the antibody-binding sites in the HA could be sufficient to
lead to the antigenic drift phenomenon. According to the study
conducted by Wilson and Cox (1990), four or five amino acid
substitutions in at least two separate antigenic sites were sufficient
for escape from pre-existent immunity and lead to vaccine updates for
human influenza A viruses. Moreover, previous studies have shown
that, in equine influenza A, 10–16 amino acid differences between
outbreak and vaccine strains could lead to a vaccine breakdown (Ito
et al., 2008; Woodward et al., 2015).
The analysis of other viral components showed the presence of
several amino acid substitutions in the polymerase complex (PB2, PB1
and PA), especially for the strains A/equine/Belfond/6-2/2009 and A/
equine/Saone-et-Loire/1/2015. A/equine/Belfond/6-2/2009 was lo-
cated within the Florida Clade 1 cluster. The amino acid substitutions
identified in A/equine/Belfond/6-2/2009 were coherent with results
obtained by Alves Beuttemmüller et al. (2016), with 21 out of 32 amino
acids substitution shared with the Florida Clade 1A/equine/Kentucky/
1/2011, A/equine/Dubai/1/2012 and A/equine/Rio Grande do Sul/1/
2012 strains.
However, it is surprising to observe such an important number of
substitutions in the polymerase complex for the French strain isolated
in 2015. Indeed, A/equine/Saone-et-Loire/1/2015 possessed 3, 13 and
11 amino acid substitutions in PB2, PB1 and PA, respectively,
compared to other French strains belonging to the Florida Clade 2
cluster (2, 2 and 6 substitutions for A/equine/Jouars/4/2006; 2, 2 and
4 substitutions for A/equine/Neuville-Pres-Sees/1/2011; 1, 1 and 4
substitutions for A/equine/Cambremer/1/2012; and 5, 5 and 6 sub-
Fig. 3. Amino acid differences between the recent French strains and the OIE-recommended vaccine strain A/equine/Richmond/1/2007.
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
5          15         25         35         45         55         65         75         85
A/equine/Belfond/6-2/2009            MEQGQDTPWI LSTEHTNIQK KGNGQQTLRL EHHNLIQSMD HFLKTMNQVG TPKQIVYWKQ WLYLKNPIPE SLKIRVLKRW R---------
A/equine/Neuville-Pres-Sees/1/2011   ...E...... .......... R......... .......... .........V .......... ..S....... ........Q. R---------
A/equine/Cambremer/1/2012            ...E...... .......... R......... .......... .........V .......... ..S....... ....H...Q. R---------
A/equine/Gironde/1/2014              ...E..I... Q.......R. R......... .Y........ .........V .......... ..S....... ........Q. R---------
A/equine/Saone-et-Loire/1/2015       ...E...... .......... .......... .......... .........V .......... ..S.....L. ....H...Q. RWFSRQEWTN
Fig. 4. Comparison of PB1-F2 amino acid sequences for French strains isolated since 2009. The strain A/equine/Belfond/6-2/2009 belonging to Florida sub-lineage Clade 1 while the
other strains belonging to Florida sub-lineage Clade 2.
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stitutions for A/equine/Gironde/1/2014). The sequence analysis of
polymerase complex protein reveals the presence of potential factors of
pathogenicity when compared to other Florida Clade 2 strains. Indeed,
a previous study carried out by Song et al. (2015) identified two
substitutions at position 224 and 383 in PA that appear to alter the
viral pathogenicity and viral replication of avian H5N1 viruses in a
mouse model. Furthermore, the N383D substitution is associated with
an increased polymerase activity in both avian and human cells.
Interestingly, all EI strains characterised here exhibit an aspartic acid
at position 383 but also the occurrence of S224P substitution for the
strain A/equine/Saone-et-Loire/1/2015. Those substitutions which
might enhance the pathogenicity and viral replication of EIV should
be monitored in future EIV characterisation.
A recent study showed the existence of a pro-inflammatory motif in
PB1-F2 from the H3N2 subtype (Alymova et al., 2011). Amino acid
residues L62, R75, R79, and L82 (C-terminus region of PB1-F2) from
H3N2 influenza A viruses were sufficient to generate an inflammatory
response. Mutations at these four positions in the C terminus region of
PB1-F2 were sufficient to abrogate PB1-F2 pro-inflammatory activity
and lead to pathogenicity attenuation. As a result, it was suggested that
some PB1-F2 non-inflammatory motifs (P62, H75, Q79 and S82) may
mitigate the risk of secondary bacterial infection (Alymova et al., 2011).
Moreover, it has been shown that the PB1-F2 pro-inflammatory motif
increased morbidity induced by primary viral infection and enhanced
development of secondary bacterial pneumonia in mice. Our study
highlights a potential pro-inflammatory motif for the strain A/equine/
Belfond/6-2/2009 (FC1; amino acid residues L62, R75 and R79) when
compared to the strains A/equine/Cambremer/1/2012 and A/equine/
Saone-et-Loire/1/2015 (both FC2), which possess a motif close to the
non-inflammatory motif (amino acid residues L62, H75, Q79 and
supplementary residue W82 for the A/equine/Saone-et-Loire/1/2015
strain). The strains A/equine/Neuville-Pres-Sees/1/2011 and A/
equine/Gironde/1/2014 have an intermediate profile with amino acid
residues L62, R75 and Q79. This transition in amino acid sequence
within the pro-inflammatory motif was described for a H3N2 strain by
Alymova et al. (2011). This transition was first identified in 1972 with
an L82S substitution, followed in 1974 by R79Q, in 1987 by R75H, and
in 1995 by L62P. These mutations were associated with a decrease in
the severity of the clinical outcomes over several decades (Doshi, 2008;
Fleming and Elliot, 2008). Our results obtained for the French strains,
follow the same transition pattern with the occurrence of substitutions
R79Q and R75H in 2011 and 2012, respectively. Moreover, our
observations on PB1-F2 were consistent with a suspected decreased
pathogenicity observed with recent Florida Clade 2. After experimental
infection with the A/equine/Cambremer/1/2012 strain, ponies dis-
played less severe clinical signs of disease, when compared to infection
with the EIV strain A/equine/Richmond/1/2007 (Garrett et al., 2016)
(Paillot, personal communication). This is in contrast with the 2009
FC1 EIV strains (i.e. A/equine/Belfond/6-2/2009 and A/equine/
Grosbois/13/2009) that caused strong morbidity and had also affected
vaccinated horses. The pathogenic EIV strain A/equine/Sussex/1/1989
(Binns et al., 1993; Livesay et al., 1993) also exhibited a motif similar
to the pro-inflammatory motif (data not shown). The P69L substitution
in A/equine/Saone-et-Loire/1/2015 PB1-F2 is also to be taken into
consideration since this isolate presents an isoleucine at position 68
and a glutamic acid in position 70. Indeed, Alymova et al. (2014a),
(2014b) recently highlighted a unique motif (I68, L69 and V70)
promoting the peptide's cytotoxicity and permeabilisation of the
mitochondrial membrane. Moreover, A/equine/Saone-et-Loire/1/
2015 PB1-F2 length is increased when compared to EIV strains
characterised recently (i.e. 90 amino acids instead of 81 amino acids).
Full-length versions of PB1-F2 (predominantly 87 or 90 amino acids)
specifically translocate into mitochondria, through their C-terminal
region, which acts as a mitochondrial targeting sequence, and induces
apoptosis (Yoshizumi et al., 2014).
5. Conclusion
The EIV strains responsible for the EI outbreaks in France since
1967 were relatively close to viruses circulating in Europe at the time.
This study reports the first introduction of viruses belonging to
Eurasian and American lineages in France in 1999. A predominance
of EIV strains belonging to the Florida Clade 2 was recorded since 2005
although the presence of Clade 1 was observed in 2009. The last cases
of EIV registered in France (2012–2015) were mainly associated with
horse movement and importation. The French EIV strain isolated in
2015 showed 3 amino acid substitutions in 2 separate antigenic sites.
These substitutions may increase the risk of vaccine breakdown.
However, it is unclear whether these substitutions will remained.
This strain also appears to be of interest due to the presence of
pathogenicity markers in PA and two motifs similar to the non-
inflammatory and cytotoxic motifs in PB1-F2. The results obtained
would suggest that monitoring these particular substitutions is im-
portant in order to anticipate the potential impact of future EIV
antigenic drift on vaccine protection (primarily HA and NA).
Furthermore, monitoring the potential novel virulence and transmis-
sion determinants in other genes could provide additional information
in determining and preventing possible future EIV outbreaks.
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